SEC Comment Letter for Edesa Biotech, Inc. (EDSA) (CIK 0001540159) (EDSA) — Jun 14, 2018
Edesa Biotech, Inc. (EDSA) (CIK 0001540159)
Date: June 14, 2018 · CIK: 0001540159 · Accession: 0000000000-18-018283
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225450
Letter
June 13, 2018 Kathi Niffenegger Chief Financial Officer Stellar Biotechnologies, Inc. 332 E. Scott Street Port Hueneme, California 93041 Re:Stellar Biotechnologies, Inc. Registration Statement on Form S-1 Filed June 6, 2018 File No. 333-225450 Dear Ms. Niffenegger: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Barbara A. Jones - Greenberg Traurig, LLP
Show Raw Text
June 13, 2018
Kathi Niffenegger
Chief Financial Officer
Stellar Biotechnologies, Inc.
332 E. Scott Street
Port Hueneme, California 93041
Re:Stellar Biotechnologies, Inc.
Registration Statement on Form S-1
Filed June 6, 2018
File No. 333-225450
Dear Ms. Niffenegger:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Barbara A. Jones - Greenberg Traurig, LLP